23616-33-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-1,6-naphthyridine is used as a building block for the synthesis of various pharmaceutical products due to its potential therapeutic properties. Its antimicrobial, antioxidant, and antitumor activities contribute to the development of new drugs for treating various diseases and conditions.
Used in Antimicrobial Applications:
2-Chloro-1,6-naphthyridine is used as an antimicrobial agent for its ability to inhibit the growth of microorganisms, making it a potential candidate for the development of new antibiotics and antifungal agents.
Used in Antioxidant Applications:
As an antioxidant, 2-Chloro-1,6-naphthyridine is used to neutralize free radicals and protect cells from oxidative damage, which can contribute to the development of age-related diseases and other health conditions.
Used in Antitumor Applications:
2-Chloro-1,6-naphthyridine is used as an antitumor agent for its potential to inhibit tumor growth and progression, making it a promising candidate for the development of new cancer therapies.
Used in Pesticide Industry:
2-Chloro-1,6-naphthyridine has been investigated for its use as a pesticide, leveraging its antimicrobial properties to control pests and protect crops.
It is important to handle 2-Chloro-1,6-naphthyridine with care due to its potential health hazards and environmental impact. Proper safety measures should be taken during its production, use, and disposal to minimize any adverse effects.

InChI:InChI=1/C8H5ClN2/c9-8-2-1-6-5-10-4-3-7(6)11-8/h1-5H

Upstream product

• 23616-29-7 1,6-naphthyridin-2(1H)-one 
• 13534-98-0 3-bromopyridin-4-amine 

Downstream Products

• 17965-81-0 2-amino-1,6-naphthyridine 

Relevant academic research and scientific papers

PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES

Pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts are disclosed, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha- synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, the compounds are used as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. Futher, the compounds are useful for measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.

NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS

Unsaturated nitrogen heterocyclic compounds of formula (I): (I), as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

Integrin expression inhibitors

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

INTEGRIN EXPRESSION INHIBITORS

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, -CH=CH- or - (CR4bR5b)mb- (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or -CO-NH-; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.